Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving
inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This
prompts new treatments of ALS. RNS60 is an experimental drug with favorable effects in
preclinical studies of neuroinflammation and neurodegeneration. Based on significant efficacy
demonstrated in preclinical studies and its excellent clinical safety profile, RNS60 is a
promising candidate for a drug to treat ALS. Developing a pharmacodynamic marker will be a
first and important step for dose finding and exploration of the mechanism of action in
human, and pave the way to trials measuring drug efficacy.
The Investigator propose a multicenter, randomized, double-blind, placebo-controlled,
parallel group, Phase II trial. The study centers will be located in Italy and at
Massachusetts General Hospital (MGH) in Boston. A total of 142 ALS patients will be randomly
assigned to RNS60 or placebo (administered by intravenous infusion once/week and inhaled via
nebulization every morning for 24 weeks). All participants will also take riluzole (50-mg
tablet twice/day). Blood samples for biomarker analysis (protein, RNA) will be collected in
the screening period, on day 1, week 4,12 and 24. Both safety and potential therapeutic
effects of RNS60 will be also assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research